January 2, 1988European Heart Journal
Mechanisms for the in vivo antiplatelet effects of isosorbide dinitrate
Why the study?
Do isosorbide dinitrate and its metabolites inhibit platelet aggregation and thromboxane B2 generation in vitro?
Population
In vitro platelet model
Comparison
Isosorbide dinitrate and its main hepatic… vs Compared against each other
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
May explain ISDN's in vivo antiplatelet effects via metabolite synergy; leaves open human translation.
Structured PICO
Do isosorbide dinitrate and its metabolites inhibit platelet aggregation and thromboxane B2 generation in vitro?
P
Population
In vitro platelet model
I
Intervention
Isosorbide dinitrate (ISDN) and its main hepatic metabolites, isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN)
C
Comparator
Compared against each other
O
Outcome
Inhibition of platelet aggregation and thromboxane B2 generation in response to ADP, adrenaline, collagen, thrombin and arachidonic acidsurrogate
The generation of the active metabolite IS-2-MN and synergism with prostacyclin explain the greater in vivo antiplatelet efficacy of isosorbide dinitrate compared to its in vitro effects.
Cite This Study
Caterina et al. (1988) studied this question.